

## Pharma Chem Ltd.

ISO-9001 - 2015 - ISO-14001 - 2015

LINK PHARMA CHEM LIMITED CIN: L24230GJ1984PLC007540

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2024

(Rs in Lakhs)

Sr. No.	Particulars		Year ended		
		30th June 2024	31st March, 2024	30th June 2023	31st March 2024
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
1	Revenue from operations	884.63	803.24	787.63	2,989.77
	Other income	27.16	(1.05)	30.66	64.03
	Total Income (A)	911.80	802.19	818.29	3,053.80
2	Expenses:				
	Cost of materials consumed	499.56	473.76	210.21	1,436.95
	Changes in inventories of finished goods and work-in- progress	7.63	(95.14)	345.79	231.14
	Employee benefits expense	130.81	141.91	133.21	551.61
	Finance costs	22.03	19.48	22.87	87.20
	Depreciation and amortization expense	23.54	24.92	25.76	103.42
	Other Expenses	192.19	190.71	194.67	835.05
	Total expenses (B)	875.76	755.64	932.50	3,245.37
3	(Loss)/Profit before tax (C) = (A-B)	36.03	46.55	(114.21)	(191.57)
4	Tax expense:				
	(1) Current tax	(-)	*	* 1	-
	(2) Short/(Excess) Provision of tax relating to earlier Year		25		0.63
	(3) Deferred tax	6.39	20.55	(31.92)	(55.92)
	Total tax expense (D)	6.39	20.55	(31.92)	(55.29)
5	(Loss)/Profit for the year/period (E) = (C-D)	29.64	26.00	(82.29)	(136.29)
	Other Comprehensive Income				
	Items that will not be reclassified to profit or loss				
	Net fair value gain on equity instruments through Other Comprehensive Income	0.16	0.04	0.15	0.38
	Remeasurement (loss) / gain of the defined benefit	1.02	15.34	(3.75)	4.09
	Income tax effect on above	(0.32)	(4.07)	0.94	(1.22)
	Total other comprehensive income for the year/period, net of tax (F)	0.86	11.31	(2.67)	3.25
7	Total comprehensive income for the year/period (Net of Tax) (E+F)	30.50	37.31	(84.96)	(133.04)
8	Paid up Equity share capital of Rs 10 each	444.06	444.06	444.06	444.06
9	Other Equity				926.81
10	Earnings per equity share (FV of Rs. 10) (Rs.) Basic and Diluted	0.67	0.59	(1.85)	(3.07)







## Pharma Chem Ltd.

ISO-9001 - 2015 - ISO-14001 - 2015

## Notes:

- 1 The above financial results for the quarter ended on June 30th, 2024 have been reviewed by Statutory auditors, recommended by the Audit Committee and have been approved and were taken on record by the Board of Directors at its meeting held on August 09th, 2024.
- 2 The Company's operations fall under single segment namely "Manufacture and Sale of Chemicals".
- 3 As per the Ind AS 109 'Financial Instruments', the investment of the Company are valued at market prices and the difference between the cost and market value of the investments are accounted as part of Other Income. The break up of the reported figures are arrived as per working given hereunder.

	Quarter ended			Year ended
Particulars	30th June 2024 (Unaudited)	31st March, 2024 (Audited)	30th June 2023 (Unaudited)	31st March 2024 (Audited)
Other income (A)	27.16	(1.05)	30.66	64.03
Net Gain/(loss) arising on financial asset designated as at FVTPL (B)	23.23	(10.07)	26.43	49.21
Adjusted Other Income (A-B)	3.93	9.02	4.23	14.82

4 The figures for the quarter ended March 31, 2024 are the balancing figures between the audited figures in respect of full financial year and the published year to date figures upto the third quarter of the relevant financial year.

Date: August 9th,2024 Place: Vadodara VADOBARA PARENTE PROPERTY OF THE PROPERTY OF T

RARODA F

For Link Pharma Chem Limited

Satish G. Thakur Chairman & Whole-time Director (DIN: 00292129)